The addition of IFNβ to COVID-19 antiviral regimen might block IL-19 stimulated cytokines by downregulating IL-19 and attenuating STAT3 signaling, leading to better control of cytokine storm and the associated COVID-19 hyperinflammation condition. The gene discussed is STAT3; the disease is COVID-19.